- Home
- DNA vs RIGL Comparison
DNA vs RIGL Comparison
Compare DNA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNA | RIGL |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.3M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | DNA | RIGL |
|---|---|---|
| Price | $9.65 | $37.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $10.50 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 950.4K | 585.3K |
| Earning Date | 02-24-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | $180,606,000.00 | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | $3.07 | $0.22 |
| P/E Ratio | ★ N/A | $6.05 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $5.00 | $15.50 |
| 52 Week High | $17.58 | $52.24 |
Technical Indicators
Market Signals| Indicator | DNA | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.16 | 39.27 |
| Support Level | $9.39 | $37.00 |
| Resistance Level | $10.00 | $39.49 |
| Average True Range (ATR) | 0.50 | 2.62 |
| MACD | 0.14 | -0.73 |
| Stochastic Oscillator | 65.60 | 4.46 |
Price Performance
Historical ComparisonAbout DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.